ClinicalTrials.gg
CompletedNCT06947408Updated Jun 9, 2026

A Study to Evaluate the Safety and Tolerability of Multiple Dose of IBI3002 in Healthy and Asthmatic Participants

A Phase 1 interventional study of Placebo and IBI3002 in Asthma, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-09.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 251 studies in Asthma with a site in China — 87 open to participants now, 96 under way, 15 of them phase 3. Asthma · China.

Enrollment
149th of 182
44 · median 203
Started
2025
with 31 others
Phase 1
31 of 251
3 open now
Registered
204th of 251
by date

Among the 251 studies in Asthma with a site in China, this one is the 149th largest by enrollment of the 182 interventional ones that give a count, is one of 32 that started in 2025, is one of 31 in phase 1, and was the 204th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

87 of the 251 studies in Asthma with a site in China are open now. Recruiting first, the newest first:

82 more — sign in →

All 87 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 251 studies in Asthma with a site in China, or all of them as a file.
02

Study summary

This study is a randomized, double-blind, placebo-controlled multiple dose ascending study in healthy participants and patients with asthma. Healthy participants will be enrolled in Part A and patients with asthma in Part B:

  1. Part A: 40 healthy participants will be enrolled across 5 cohorts, including 5 different dose levels. In each cohort, there will be 8 participants randomized at a ratio of 6:2 to receive IBI3002 or matched placebo. The study consists of a screening period, a double-blind treatment period and a safety follow-up period. The study has a total duration of approximately 12 to 14 weeks.
  2. Part B: 20 patients with asthma will be enrolled across 2 cohorts. In each cohort, there will be 10 participants randomized at a ratio of 8:2 to receive IBI3002 or matched placebo. The study consists of a screening period, a double-blind treatment period and a safety follow-up period. The study has a total duration of approximately 16 weeks.
03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. (Part A and B) The body weight of men ≥ 50kg, and of women ≥ 45kg; (BMI) between 18 and 32 kg/m2 (including cut-off values).
  2. (Part B) Diagnosed with asthma for at least 12 months according to the Global Initiative for Asthma (GINA) and confirmed by the Investigator.
  3. (Part B) Evidence of airway reversibility within 5 years prior to screening, including but not limited to a positive bronchodilation test or bronchoprovocation test. If the historical results are not available, tests during the screening period will also be accepted.
  4. (Part B) Medium-high dose ICS therapy (defined as a daily dose of ≥250μg fluticasone propionate or equivalent ICS dose) in combination with at least one second controller [e.g., LABA, LAMA, or LTRA for at least 3 months with a stable dose for at least 1 month prior to randomization.
  5. (Part B) Pre-BD ≤ 80% of prediction.

Exclusion criteria

Exclusion Criteria:

  1. (Part A and B) Diseases that have an impact on the participant's own safety or participation in the study as judged by the investigator. This includes, but not limited to, mental disorders, diseases of the central nervous system, cardiovascular system, digestive system, respiratory system, urinary system, blood system, or metabolic system.
  2. (Part A and B) Participants with known history of active tuberculosis or clinical suspicion of tuberculosis (including but not limited to pulmonary tuberculosis, lymph node tuberculosis, tuberculous pleurisy, etc.); or positive T-SPOT.TB during the screening period, or evidence of suspected tuberculosis on chest imaging, or any other clinical evidence of latent tuberculosis.
  3. (Part A and B) A history of , except for localized basal cell carcinoma (BCC) or squamous cell carcinoma (SCC) of the skin that has been resected or cured.
  4. (Part B) History of a life-threatening asthma attack requiring mechanical ventilation, and/or an asthma attack related to hypercapnia, respiratory failure, or hypoxic epilepsy within 5 years prior to screening.
  5. (Part B) History of an asthma worsening or exacerbation that resulted in an visit to emergency room or hospitalization, or an increase in asthma controller, or requiring any systemic therapy within 3 months prior to screening.

The above information is not intended to contain all considerations relevant to a participant's potential participation in this trial.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    Part B IBI3002 dose 5 SC

    Patients with asthma will receive IBI3002 dose 5 SC at Week 0, 2, 4, 6, 8 and 10

    Drug: IBI3002

  • Placebo comparator
    Part B Placebo

    Patients with asthma will receive matched placebo

    Drug: Placebo

  • Experimental
    Part A IBI3002 dose2 SC

    Healthy Participants will receive IBI3002 dose 2 SC at Week 0, 2, 4, and 6

    Drug: IBI3002

  • Experimental
    Part A IBI3002 dose 4 SC

    Healthy Participants will receive IBI3002 dose 4 SC at Week 0, 2, 4, and 6

    Drug: IBI3002

  • Experimental
    Part B IBI3002 dose 2 SC

    Patients with asthma will receive IBI3002 dose 2 SC at Week 0, 2, 4, 6, 8 and 10

    Drug: IBI3002

  • Placebo comparator
    Part A Placebo

    Healthy Participants will receive matched placebo

    Drug: Placebo

  • Experimental
    Part A IBI3002 dose 3 IV

    Healthy Participants will receive IBI3002 dose 3 IV at Week 0, 2, 4, and 6

    Drug: IBI3002

  • Experimental
    Part A IBI3002 dose 5 SC

    Healthy Participants will receive IBI3002 dose 5 SC at Week 0, 2, 4, and 6

    Drug: IBI3002

  • Experimental
    Part A IBI3002 dose1 SC

    Healthy Participants will receive IBI3002 dose1 SC at Week 0, 4 and 8

    Drug: IBI3002

Interventions

  • DrugPlacebo

    Healthy participants and patients with asthma will receive matched placebo.

  • Healthy participants and patients with asthma will receive IBI3002 at the corresponding dose and dosing interval.

06

What researchers measure

Primary outcomes

  1. To evaluate the Incidence of sudden adverse events of healthy participants and patients with asthma receiving IBI3002 multiple ascending doses.

    Incidence of adverse events (AEs) and serious adverse events (SAEs) after IBI3002 multiple doses in healthy participants;

    Time frame: baseline to Week16

Secondary outcomes

  1. To assess PK parameters of healthy participants and patients with asthma receiving IBI3002 multiple ascending doses.

    PK parameters include, the maximum concentration (Cmax), after multiple doses.

    Time frame: baseline to Week16

  2. To assess PK parameters of healthy participants and patients with asthma receiving IBI3002 multiple ascending doses.

    PK parameters include, the time to achieve Cmax (Tmax), after multiple doses.

    Time frame: baseline to Week16

  3. To assess PK parameters of healthy participants and patients with asthma receiving IBI3002 multiple ascending doses.

    PK parameters include, the area under the concentration-time curve (AUC) ,after multiple doses.

    Time frame: baseline to Week16

  4. To assess PK parameters of healthy participants and patients with asthma receiving IBI3002 multiple ascending doses.

    PK parameters include the trough concentration (Cmin) after multiple doses.

    Time frame: baseline to Week16

  5. To assess the incidence of immunogenicity of healthy participants and patients with asthma receiving IBI3002 multiple ascending doses.

    the incidence of immunogenicity of IBI3002.

    Time frame: baseline to Week16

07

Study locations

1 site
  • China-japan Friendship Hosipital
    Beijing, Beijing Municipality 100192, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2025 to primary completion in May 2026, 11 months.

Of 173 industry-sponsored phase 1 interventional studies under Asthma, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 11 months is above that.

Counting every sponsor, half of 200 studies reached it within 6 months; a quarter within 3 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2025
First posted
Apr 27, 2025
StartActual
May 14, 2025
Primary completionActual
May 11, 2026
CompletionActual
May 11, 2026
Last update
Jun 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06947408
Responsible party
Sponsor
First posted
Apr 27, 2025
Start date
May 14, 2025
Primary completion
May 11, 2026
Completion
May 11, 2026
Last update
Jun 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: IBI3002

Start the discussion